Arcus Biosciences Operating Margin 2017-2022 | RCUS
Current and historical operating margin for Arcus Biosciences (RCUS) over the last 10 years. The current operating profit margin for Arcus Biosciences as of March 31, 2022 is 14.67%.
| Arcus Biosciences Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2022-03-31 |
$0.39B |
$0.06B |
15.38% |
| 2021-12-31 |
$0.38B |
$0.05B |
14.17% |
| 2021-09-30 |
$0.04B |
$-0.28B |
-775.00% |
| 2021-06-30 |
$0.09B |
$-0.20B |
-216.30% |
| 2021-03-31 |
$0.09B |
$-0.17B |
-197.65% |
| 2020-12-31 |
$0.08B |
$-0.12B |
-157.69% |
| 2020-09-30 |
$0.08B |
$-0.09B |
-112.66% |
| 2020-06-30 |
$0.02B |
$-0.11B |
-712.50% |
| 2020-03-31 |
$0.02B |
$-0.10B |
-612.50% |
| 2019-12-31 |
$0.02B |
$-0.09B |
-556.25% |
| 2019-09-30 |
$0.01B |
$-0.08B |
-1050.00% |
| 2019-06-30 |
$0.01B |
$-0.07B |
-730.00% |
| 2019-03-31 |
$0.01B |
$-0.06B |
-666.67% |
| 2018-12-31 |
$0.01B |
$-0.05B |
-675.00% |
| 2018-09-30 |
$0.01B |
$-0.05B |
-771.43% |
| 2018-06-30 |
$0.00B |
$-0.07B |
-2166.67% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.901B |
$0.383B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
